Jun 28 |
Regeneron lymphoma antibody drug endorsed for conditional approval in EU
|
Jun 28 |
Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
|
Jun 27 |
Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024
|
Jun 27 |
3 Biotech Stocks That Could Make Your Grandchildren Rich
|
Jun 26 |
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
|
Jun 25 |
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Could Be 45% Below Their Intrinsic Value Estimate
|
Jun 24 |
5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
|
Jun 24 |
Pipeline Moves: Approval prospects for BioTissue’s diabetic foot ulcer drug up after Phase III completion
|
Jun 21 |
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
|
Jun 21 |
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for June 2024
|